<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000630913"><TermName>alvocidib</TermName><TermPronunciation>(al-VOH-sih-dib)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of several types of cancer. It stops cells from dividing and may kill cancer cells. It is a type of cyclin-dependent kinase (CDK) inhibitor. Also called flavopiridol and HMR 1275.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000722548" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;alvocidib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000722547" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;alvocidib&quot;" language="es" id="_4"/><SpanishTermName>alvocidib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de cáncer. Impide que las células se multipliquen y puede destruir células cancerosas. Es un tipo de inhibidor de la cinasa dependiente de ciclinas (CDK). También se llama flavopiridol y HMR 1275.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-02-12</DateFirstPublished><DateLastModified>2009-02-12</DateLastModified></GlossaryTerm>
